Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2013, Article ID 613086, 13 pages
http://dx.doi.org/10.1155/2013/613086
Review Article

Genetics of Psoriasis and Pharmacogenetics of Biological Drugs

1Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain
2Servicio de Dermatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain
3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28006 Madrid, Spain

Received 3 May 2013; Accepted 19 July 2013

Academic Editor: Jozélio Freire De Carvalho

Copyright © 2013 Rocío Prieto-Pérez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Yamamoto, Y. Imai, Y. Sakaguchi, T. Haneda, and K. Yamanishi, “Serum cytokines correlated with the disease severity of generalized pustular psoriasis,” Disease Markers, vol. 34, no. 3, pp. 153–161, 2013. View at Google Scholar
  2. A. Julia, R. Tortosa, and J. M. Hernanz, “Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes,” Human Molecular Genetics, vol. 21, no. 20, pp. 4549–4557, 2012. View at Google Scholar
  3. P. Schafer, “Apremilast mechanism of action and application to psoriasis and psoriatic arthritis,” Biochemical Pharmacology, vol. 83, no. 12, pp. 1583–1590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Dauden, E. Herrera, and L. Puig, “Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire,” Health and Quality of Life Outcomes, vol. 10, p. 56, 2012. View at Google Scholar
  5. P. Zhang, M. Zhao, and G. Liang, “Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris,” Journal of Autoimmunity, 2013. View at Google Scholar
  6. V. Chandran and S. P. Raychaudhuri, “Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis,” Journal of Autoimmunity, vol. 34, no. 3, pp. J314–J321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Chandran, “Genetics of psoriasis and psoriatic arthritis,” Indian Journal of Dermatology, vol. 55, no. 2, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Prieto-Perez, T. Cabaleiro, E. Dauden, and F. Abad-Santos, “Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases,” Pharmacogenomics Journal, 2013. View at Google Scholar
  9. S. P. Raychaudhuri, “Role of IL-17 in psoriasis and psoriatic arthritis,” Clinical Reviews in Allergy & Immunology, vol. 44, no. 2, pp. 183–193, 2012. View at Google Scholar
  10. K. Ortiz-Ibanez, M. M. Alsina, and C. Munoz-Santos, “Tofacitinib and other kinase inhibitors in the treatment of psoriasis,” Actas Dermo-Sifiliográficas, vol. 104, no. 4, pp. 304–310, 2013. View at Google Scholar
  11. R. Vafadari, W. Weimar, and C. C. Baan, “Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway,” Clinica Chimica Acta, vol. 413, no. 17-18, pp. 1398–1405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. K. West, “CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders,” Current Opinion in Investigational Drugs, vol. 10, no. 5, pp. 491–504, 2009. View at Google Scholar · View at Scopus
  13. D. Wojciechowski and F. Vincenti, “Targeting JAK3 in kidney transplantation: current status and future options,” Current Opinion in Organ Transplantation, vol. 16, no. 6, pp. 614–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Vasilopoulos, M. Manolika, E. Zafiriou et al., “Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the greek population,” Molecular Diagnosis and Therapy, vol. 16, no. 1, pp. 29–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Tejasvi, P. E. Stuart, V. Chandran et al., “TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis,” Journal of Investigative Dermatology, vol. 132, no. 3, pp. 593–600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. K. Kulski, W. Kenworthy, M. Bellgard et al., “Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals,” Journal of Molecular Medicine, vol. 83, no. 12, pp. 964–975, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Iizuka, H. Takahashi, M. Honma, and A. Ishida-Yamamoto, “Unique keratinization process in psoriasis: late differentiation markers are abolished because of the premature cell death,” Journal of Dermatology, vol. 31, no. 4, pp. 271–276, 2004. View at Google Scholar · View at Scopus
  18. J. G. Krueger, S. Fretzin, M. Suarez-Farinas et al., “IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis,” Journal of Allergy and Clinical Immunology, vol. 130, no. 1, pp. 145–154, 2012. View at Google Scholar
  19. T. Hohler, A. Kruger, P. M. Schneider et al., “A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis,” Journal of Investigative Dermatology, vol. 109, no. 4, pp. 562–565, 1997. View at Google Scholar · View at Scopus
  20. R. Mössner, K. Kingo, A. Kleensang et al., “Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris,” Journal of Investigative Dermatology, vol. 124, no. 1, pp. 282–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Louis, D. Franchimont, A. Piron et al., “Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans,” Clinical and Experimental Immunology, vol. 113, no. 3, pp. 401–406, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Li, G. Wang, Y. Gao, L. Liu, and T. Gao, “TNF-α gene promoter −238G>A and −308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis,” Journal of Investigative Dermatology, vol. 127, no. 8, pp. 1886–1892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Kaluza, E. Reuss, S. Grossmann et al., “Different transcriptional activity and in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism,” Journal of Investigative Dermatology, vol. 114, no. 6, pp. 1180–1183, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Reich, R. Mössner, I. R. König, G. Westphal, A. Ziegler, and C. Neumann, “Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset,” Journal of Investigative Dermatology, vol. 118, no. 1, pp. 155–163, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Settin, H. Hassan, R. El-Baz, and T. Hassan, “Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt,” Acta Dermatovenerologica Alpina, Pannonica et Adriatica, vol. 18, no. 3, pp. 105–112, 2009. View at Google Scholar · View at Scopus
  26. T.-G. Kim, C.-W. Pyo, S.-S. Hur et al., “Polymorphisms of tumor necrosis factor (TNF) α and β genes in Korean patients with psoriasis,” Archives of Dermatological Research, vol. 295, no. 1, pp. 8–13, 2003. View at Google Scholar · View at Scopus
  27. K. Reich, G. Westphal, T. Schulz et al., “Combined analysis of polymorphisms of the tumor necrosis factor-α and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis,” Journal of Investigative Dermatology, vol. 113, no. 2, pp. 214–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Nedoszytko, A. Szczerkowska-Dobosz, M. Zabłotna, J. Gleń, K. Rȩbała, and J. Roszkiewicz, “Associations of promoter region polymorphisms in the tumour necrosis factor-α gene and early-onset psoriasis vulgaris in a northern Polish population,” British Journal of Dermatology, vol. 157, no. 1, pp. 165–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. I. Arias, B. Giles, T. H. Eiermann, W. Sterry, and J. P. Pandey, “Tumor necrosis factor-alpha gene polymorphism in psoriasis,” Experimental and Clinical Immunogenetics, vol. 14, no. 2, pp. 118–122, 1997. View at Google Scholar · View at Scopus
  30. C. Johansen, H. Vinter, L. Soegaard-Madsen et al., “Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy,” British Journal of Dermatology, vol. 163, no. 6, pp. 1194–1204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. É. Toussirot, “The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases,” Inflammation and Allergy, vol. 11, no. 2, pp. 159–168, 2012. View at Google Scholar · View at Scopus
  32. M. Kurzeja, L. Rudnicka, and M. Olszewska, “New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab,” American Journal of Clinical Dermatology, vol. 12, no. 2, pp. 113–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Li and A. B. Begovich, “Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis,” Seminars in Immunology, vol. 21, no. 6, pp. 318–327, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. V. E. Garcia, M. Chang, R. Brandon et al., “Detailed genetic characterization of the interleukin-23 receptor in psoriasis,” Genes and Immunity, vol. 9, no. 6, pp. 546–555, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. X.-J. Zhang, “Enlightenment from genome-wide association study to genetics of psoriasis,” Journal of Zhejiang University, vol. 38, no. 4, pp. 333–337, 2009. View at Google Scholar · View at Scopus
  36. R. P. Nair, A. Ruether, P. E. Stuart et al., “Polymorphisms of the IL12B and IL23R genes are associated with psoriasis,” Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1653–1661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Cargill, S. J. Schrodi, M. Chang et al., “A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes,” American Journal of Human Genetics, vol. 80, no. 2, pp. 273–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. P. Nair, P. E. Stuart, P. Kullavanijaya et al., “Genetic evidence for involvement of the IL23 pathway in Thai psoriatics,” Archives of Dermatological Research, vol. 302, no. 2, pp. 139–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Wu, Z. Lu, Y. Chen, F. Xue, X. Chen, and J. Zheng, “Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population,” Human Immunology, vol. 71, no. 12, pp. 1255–1258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Capon, P. Di Meglio, J. Szaub et al., “Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis,” Human Genetics, vol. 122, no. 2, pp. 201–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. R. L. Smith, R. B. Warren, S. Eyre et al., “Polymorphisms in the IL-12β and IL-23R genes are associated with psoriasis of early onset in a UK cohort,” Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1325–1327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Liu, C. Helms, W. Liao et al., “A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci,” PLoS Genetics, vol. 4, no. 3, Article ID e1000041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Hüffmeier, J. Lascorz, B. Böhm et al., “Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis,” Journal of Investigative Dermatology, vol. 129, no. 2, pp. 355–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. P. Nair, K. C. Duffin, C. Helms et al., “Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways,” Nature Genetics, vol. 41, no. 2, pp. 199–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Ellinghaus, D. Ellinghaus, P. E. Stuart et al., “Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2,” Nature Genetics, vol. 42, no. 11, pp. 991–995, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Tsunemi, H. Saeki, K. Nakamura et al., “Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris,” Journal of Dermatological Science, vol. 30, no. 2, pp. 161–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. L. Musone, K. E. Taylor, J. Nititham et al., “Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases,” Genes and Immunity, vol. 12, no. 3, pp. 176–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. J. P. Lodolce, L. E. Kolodziej, L. Rhee et al., “African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity,” Journal of Immunology, vol. 184, no. 12, pp. 7001–7009, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. U. Hüffmeier, S. Uebe, A. B. Ekici et al., “Comon variants at TRAF3IP2 are asociated with susceptibility to psoriatic arthritis and psoriasis,” Nature Genetics, vol. 42, no. 11, pp. 996–999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Strange, F. Capon, C. C. A. Spencer et al., “A genome-wide asociation study identifies new psoriasis susceptibility loci and an interaction betwEn HLA-C and ERAP1,” Nature Genetics, vol. 42, no. 11, pp. 985–990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. B.-J. Feng, L.-D. Sun, R. Soltani-Arabshahi et al., “Multiple loci within the major histocompatibility complex confer risk of psoriasis,” PLoS Genetics, vol. 5, no. 8, Article ID e1000606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. L. D. Sun, H. Cheng, and Z. X. Wang, “Association analyses identify six new psoriasis susceptibility loci in the Chinese population,” Nature Genetics, vol. 42, no. 11, pp. 1005–1009, 2010. View at Google Scholar
  53. Y.-K. Kim, C.-W. Pyo, H.-B. Choi, S.-Y. Kim, T.-Y. Kim, and T.-G. Kim, “Associations of IL-2 and IL-4 gene polymorphisms with psoriasis in the Korean population,” Journal of Dermatological Science, vol. 48, no. 2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Baran, J. C. Szepietowski, G. Mazur, and E. Baran, “IFN-γ promoter gene polymorphism in psoriasis vulgaris,” Biomarkers, vol. 13, no. 1, pp. 52–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Kanda, N. Masahiro, Y. Tada, T. Ishikawa, S. Sato, and S. Watanabe, “Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells,” Journal of Leukocyte Biology, vol. 89, no. 6, pp. 935–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. E. J. Hollox, U. Huffmeier, P. L. J. M. Zeeuwen et al., “Psoriasis is associated with increased β-defensin genomic copy number,” Nature Genetics, vol. 40, no. 1, pp. 23–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. Web page National Center for Biotecnology Information (NCBI), 2013, http://www.ncbi.nlm.nih.gov/gene.
  58. T. Kato, Y. Tsunemi, H. Saeki et al., “Interferon-18 gene polymorphism -137 G/C is associated with susceptibility to psoriasis vulgaris but not with atopic dermatitis in Japanese patients,” Journal of Dermatological Science, vol. 53, no. 2, pp. 162–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Baran, J. C. Szepietowski, G. Mazur, and E. Baran, “IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris,” Acta Dermato-Venereologica, vol. 88, no. 2, pp. 113–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. N. M. Craven, C. W. Jackson, B. Kirby et al., “Cytokine gene polymorphisms in psoriasis,” British Journal of Dermatology, vol. 144, no. 4, pp. 849–853, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Chang, Y. Li, C. Yan et al., “Variants in the 5q31 cytokine gene cluster are associated with psoriasis,” Genes and Immunity, vol. 9, no. 2, pp. 176–181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. K. C. Duffin, I. C. Freeny, S. J. Schrodi et al., “Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking,” The Journal of investigative dermatology, vol. 129, no. 12, pp. 2777–2783, 2009. View at Google Scholar · View at Scopus
  63. J. Bowes, S. Eyre, E. Flynn et al., “Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1016–1019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Kõks, K. Kingo, R. Rätsep, M. Karelson, H. Silm, and E. Vasar, “Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis,” Genes and Immunity, vol. 5, no. 8, pp. 662–667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. X.-Y. Chen, L.-W. Jin, Y.-W. Chen et al., “The association between the IL-20 -1723C→G allele on the 1q chromosome and psoriasis triggered or exacerbated by an upper respiratory tract infection in the Chinese Han population,” Dermatology, vol. 222, no. 1, pp. 24–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Kingo, S. Kõks, T. Nikopensius, H. Silm, and E. Vasar, “Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis,” Genes and Immunity, vol. 5, no. 2, pp. 117–121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Kingo, R. Mössner, T. Traks et al., “Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis,” Journal of Dermatological Science, vol. 57, no. 1, pp. 71–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Kõks, K. Kingo, K. Vabrit et al., “Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis,” Genes and Immunity, vol. 6, no. 5, pp. 407–415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. X.-J. Zhang, K.-L. Yan, Z.-M. Wang et al., “Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population,” Journal of Investigative Dermatology, vol. 127, no. 11, pp. 2544–2551, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. R. L. Smith, S. Eyre, R. B. Warren, H. S. Young, C. E. M. Griffiths, and J. Worthington, “No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients,” Journal of Investigative Dermatology, vol. 128, no. 12, pp. 2904–2905, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Wang, L. Yang, L. Gao, T. W. Gao, W. Li, and Y. F. Liu, “A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis,” International Journal of Immunogenetics, vol. 35, no. 1, pp. 45–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. M. I. Zervou, G. N. Goulielmos, F. Castro-Giner, A. D. Tosca, and S. Krueger-Krasagakis, “STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece,” Human Immunology, vol. 70, no. 9, pp. 738–741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Karpouzis, R. Caridha, G. Tripsianis, C. Michailidis, G. Martinis, and S. V. Veletza, “Apolipoprotein e gene polymorphism in psoriasis,” Archives of Dermatological Research, vol. 301, no. 6, pp. 405–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Coto-Segura, E. Coto, V. Alvarez et al., “Apolipoprotein ε4 allele is associated with psoriasis severity,” Archives of Dermatological Research, vol. 302, no. 2, pp. 145–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Campalani, M. H. Allen, D. Fairhurst et al., “Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin,” British Journal of Dermatology, vol. 154, no. 2, pp. 345–352, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. J. A. Halsall, J. E. Osborne, J. H. Pringle, and P. E. Hutchinson, “Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis,” Pharmacogenetics and Genomics, vol. 15, no. 5, pp. 349–355, 2005. View at Google Scholar · View at Scopus
  77. N. M. Zuel-Fakkar, M. M. Kamel, M. K. Asaad, M. Z. Mahran, and A. A. Shehab, “A study of ApaI and TaqI genotypes of the vitamin D receptor in Egyptian patients with psoriasis,” Clinical and Experimental Dermatology, vol. 36, no. 4, pp. 355–359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Rucevic, V. Barisic-Drusko, L. Glavas-Obrovac, and M. Stefanic, “Vitamin D endocrine system and psoriasis vulgaris—review of the literature,” Acta Dermatovenerologica Croatica, vol. 17, no. 3, pp. 187–192, 2009. View at Google Scholar
  79. D. Dayangac-Erden, A. Karaduman, and H. Erdem-Yurter, “Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients,” Archives of Dermatological Research, vol. 299, no. 10, pp. 487–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. W. Łuszczek, W. Kubicka, M. Jasek et al., “CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris,” International Journal of Immunogenetics, vol. 33, no. 3, pp. 217–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Łuszczek, E. Majorczyk, P. Nockowski et al., “Distribution of the CTLA-4 single nucleotide polymorphisms CT60G>A and +49A>G in psoriasis vulgaris patients and control individuals from a Polish Caucasian population,” International Journal of Immunogenetics, vol. 35, no. 1, pp. 51–55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. Y.-K. Kim, C.-W. Pyo, S.-S. Hur, T.-Y. Kim, and T.-G. Kim, “No associations of CTLA-4 and ICAM-1 polymorphisms with psoriasis in the Korean population,” Journal of Dermatological Science, vol. 33, no. 1, pp. 75–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. H. L. Hébert, F. R. Ali, J. Bowes, C. E. M. Griffiths, A. Barton, and R. B. Warren, “Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy,” British Journal of Dermatology, vol. 166, no. 3, pp. 474–482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Bowes, E. Flynn, P. Ho et al., “Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2199–2203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. X.-J. Zhang, W. Huang, S. Yang et al., “Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21,” Nature Genetics, vol. 41, no. 2, pp. 205–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Docampo, E. Giardina, E. Riveira-Muñoz et al., “Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: a study in Spanish and Italian populations and meta-analysis,” Arthritis and Rheumatism, vol. 63, no. 7, pp. 1860–1865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. L. H. Kircik and J. Q. Del Rosso, “Anti-TNF agents for the treatment of psoriasis,” Journal of Drugs in Dermatology, vol. 8, no. 6, pp. 546–559, 2009. View at Google Scholar · View at Scopus
  88. R. K. Sivamani, G. Correa, Y. Ono, M. P. Bowen, S. P. Raychaudhuri, and E. Maverakis, “Biological therapy of psoriasis,” Indian Journal of Dermatology, vol. 55, no. 2, pp. 161–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Brand, “Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease,” Gut, vol. 58, no. 8, pp. 1152–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Gandhi, E. Alwawi, and K. B. Gordon, “Anti-p40 Antibodies Ustekinumab and Briakinumab: blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis,” Seminars in Cutaneous Medicine and Surgery, vol. 29, no. 1, pp. 48–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. J. J. Wu, “Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis,” New England Journal of Medicine, vol. 367, no. 3, pp. 274–275.
  92. P. Rich, B. Sigurgeirsson, D. Thaci et al., “Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study,” British Journal of Dermatology, vol. 168, no. 2, pp. 402–411, 2013. View at Google Scholar
  93. K. A. Papp, C. Leonardi, A. Menter et al., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis,” New England Journal of Medicine, vol. 366, no. 13, pp. 1181–1189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. D. D. Patel, D. M. Lee, F. Kolbinger, and C. Antoni, “Effect of IL-17A blockade with secukinumab in autoimmune diseases,” Annals of the Rheumatic Diseases, 2012. View at Google Scholar
  95. C. Leonardi, R. Matheson, C. Zachariae et al., “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis,” New England Journal of Medicine, vol. 366, no. 13, pp. 1190–1191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. K. A. Papp, R. G. Langley, B. Sigurgeirsson et al., “Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study,” British Journal of Dermatology, vol. 168, no. 2, pp. 412–421, 2013. View at Google Scholar
  97. W. C. Ports, S. Khan, S. Lan et al., “A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis,” British Journal of Dermatology, 2013. View at Google Scholar
  98. C. J. Menet, L. V. Rompaey, and R. Geney, “Advances in the discovery of selective JAK inhibitors,” Progress in Medicinal Chemistry, vol. 52, pp. 153–223, 2013. View at Google Scholar
  99. M. J. Sanz, J. Cortijo, and E. J. Morcillo, “PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression,” Pharmacology and Therapeutics, vol. 106, no. 3, pp. 269–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Papp, J. C. Cather, L. Rosoph et al., “Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial,” Lancet, vol. 380, no. 9843, pp. 738–746, 2012. View at Google Scholar
  101. J. Bowes and A. Barton, “The genetics of psoriatic arthritis: lessons from genome-wide association studies,” Discovery Medicine, vol. 10, no. 52, pp. 177–183, 2010. View at Google Scholar · View at Scopus
  102. F. Soriguer and S. Morcillo, “Qué hacer cuando en los estudios de epidemiología biomolecular la distribución genotípica no se ajusta al equilibrio de Hardy-Weinberg,” Endocrinología y Nutrición, vol. 54, no. 3, pp. 169–173, 2007. View at Google Scholar
  103. H.-F. Zheng, X.-B. Zuo, W.-S. Lu et al., “Variants in MHC, LCE and IL12B have epistatic effects on psoriasis risk in Chinese population,” Journal of Dermatological Science, vol. 61, no. 2, pp. 124–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. H.-F. Zheng, C. Zhang, L.-D. Sun et al., “A single nucleotide polymorphism of MHC region is associated with subphenotypes of Psoriasis in Chinese population,” Journal of Dermatological Science, vol. 59, no. 1, pp. 50–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Capon, M.-J. Bijlmakers, N. Wolf et al., “Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene,” Human Molecular Genetics, vol. 17, no. 13, pp. 1938–1945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. Web page Hapmap, 2013, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap3r3_B36/#search.
  107. Web page Alfred, 2013, http://alfred.med.yale.edu/.